<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02645981</url>
  </required_header>
  <id_info>
    <org_study_id>ZGDH3</org_study_id>
    <nct_id>NCT02645981</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donafenib versus sorafenib for advanced hepatocellular cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess efficacy and safety in patients wiht advanced
      hepatocellular carcinoma (HCC).The study is a randomised,controlled,multicentre study.The
      controlled drug is sorafenib(Nexavar).The primary endpoint is overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Patient visits are scheduled every 8 weeks to monitor efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Patient visits are scheduled every 8 weeks to monitor efficacy.Progressive disease is measured from the date of randomization until dead or disease progression according to Response Evaluation Criteria in Solid Tumors(Version 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Patient visits are scheduled every 4 weeks to monitor safety and drug accountability. Patients were monitored for adverse events by use of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>Donafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:Donafenib; Dose:200mg,bid,po.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib(Nexavar)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:Sorafenib; Dose:400mg,bid,po.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects</description>
    <arm_group_label>Donafenib</arm_group_label>
    <other_name>CM4307</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Control</description>
    <arm_group_label>Sorafenib(Nexavar)</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above 18 years old;

          -  Patients with measurable, histologically or clinical proven, inoperable HCC;

          -  Patients wtih measurable lesion and proved by independent radiology committee(IRC);

          -  Child-Pugh (CP) score of 7 or less；

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less;

          -  Patients had not received prior systemic treatments for HCC;

          -  Life expectancy at least 3 months;

          -  Adequate hepatic and renal function;

          -  Adequate hematologic function (platelet count,≥75×109per liter;hemoglobin ≥9.0g per
             deciliter;neutrophil≥1.5×109per liter,);

          -  Prothrombin time international normal.

        Exclusion Criteria:

          -  Patients received operate in 3 months;

          -  Patients received transcatheter arterial chemoembolization（TACE） in 4 weeks;

          -  Patients had received systemic therapy;

          -  Patients had prior treatment with sorafenib;

          -  Central nervous system(CNS) involvement;

          -  Severe or mild-degree ascitic fluid;

          -  Main portal vein tumor thrombus;

          -  Inferior venae cava tumor thrombus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The PLA 81 Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Bi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shukui Qin, MD</last_name>
    <phone>025-80864541</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The PLA 81 Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukui Qin, MD</last_name>
      <email>qinsk@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Shukui Qin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiufeng Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Bi, MD</last_name>
      <phone>18980601771</phone>
      <email>bifeng@medmail.cn</email>
    </contact>
    <contact_backup>
      <last_name>Meng Qiu</last_name>
      <phone>18980601776</phone>
      <email>qiumeng33@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Feng Bi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng Qiu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donafeinb</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Overall Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

